Introduction {#sec1-1}
============

Diabetes mellitus is a chronic disease that may cause a long term health problem and multiple quality of life depriving complications. One of the diabetic complications is diabetic peripheral neuropathy that can be assessed by Minnesota Neuropathy Screening Instrument (MNSI). The MNSI includes two separate assessments, a 15-item self-administered questionnaire and a lower extremity examination. Diabetic peripheral neuropathy is based on the existence of chronic hyperglycemia. Chronic hyperglycemia is associated with oxidative stress, endothelium damages, and it causes microvascular and hemorheological disturbances \[[@ref1]\], \[[@ref2]\].

Oxidative stress can be determined by several ways, such as MDA. MDA is one of recommended marker for oxidative stress. MDA, a product of the lipid peroxidation, has been accepted as one of the reliable biological markers for oxidative stress, based on BOS (Biomarker Oxidative Stress) Study in 2002 \[[@ref3]\], \[[@ref4]\], \[[@ref5]\]. MDA has been documented as a primary biomarker of free radical-mediated lipid damage and oxidative stress. Increased MDA level in serum and may other tissues have been reported in diabetic patients. MDA may impact peripheral nerve among diabetic patients \[[@ref6]\], \[[@ref7]\].

NGF is an important protein to maintain life and survival of the neurons, and it works by increasing cell regeneration and decreasing the degeneration. NGF decline level is associated with the disturbances in Schwann cells regeneration because NGF produced by the neurons and the Schwann cells. NGF decline level induces peripheral nerve lesions in diabetic patients. The forms of lesions are axonal atrophy, demyelination, and reduced number of nerve fibres \[[@ref8]\], \[[@ref9]\]. Pittinger and Vinik (2003) found that a decrease of NGF serum level in diabetes correlates with the clinical symptoms of neuropathy \[[@ref10]\]. The clinical symptoms of diabetic neuropathy can be assessed with diabetic peripheral neuropathy score by Minnesota Neuropathy Screening Instruments (MNSI) \[[@ref11]\].

The objective of this study is to identify MDA serum level, NGF serum level, diabetic peripheral neuropathy score and the correlation between MDA and NGF serum level with diabetic peripheral neuropathy score.

Methods {#sec1-2}
=======

This was a cross-sectional study, conducted in the internal medicine department in Dr M. Djamil Hospital, Padang, West Sumatera, Indonesia. This study was conducted from January 2017 until December 2017.

Inclusion criteria in this study are type 2 diabetes mellitus (T2DM) patients with peripheral neuropathy, aged between 18 to 59 years old that has agreed to participate and signed the informed consent form.

Exclusion criteria in this study are patients with chronic renal disease, liver cirrhosis, stroke, Alzheimer's disease, allergic disease, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, systemic sclerosis and other autoimmune disorder, leprosy, anemia, thrombocytosis, patients currently using antituberculosis drugs, cytostatic drug, steroid, alcohol, and patients with foot ulcer that is difficult to examine.

The diabetic peripheral neuropathy score was calculated by history score in MNSI score '7' or higher and physical assessment score in MNSI more than two. The history score in MNSI is a self-fulfilled questionnaire. Physical assessment in MNSI was the appearance of feet, ulceration, ankle reflexes, vibration perception at great toe, and monofilament \[[@ref6]\]. The appearance of feet was scored 1 when there was deformities, dry skin, callus, infection, fissure.

Ulceration was score 1 when present, and scored 0 if absent.

The ankle reflexes, also known as the Achilles reflex, examined by tapped the Achilles tendon while the foot is dorsiflexed. When there was no reflex, they would get score 1, when the reflex which appeared only after assisted by Jendrassic manoeuvre, they would get score 0.5.

Vibration perception at great toe was examined by placing the fork on the projection of distal interphalangeal joint of the hallux. Subjects would tell the examiner whether they felt the vibration when it disappeared with closed eyes. When subjects did not report any vibration, the score was zero. When the subjects felt the vibration less than 10 seconds, they would get score 0.5.

The monofilament testing was done on ten points in each foot. The monofilament was perpendicular and pressed for two seconds only, while the subjects closed their eyes. All points would be tested for three times. Score zero would be given for eight right answers or more, and a half point for one to seven right answers.

MDA and NGF serum level were measured by laboratory methods. About 3 mL blood samples were taken from the cubital vein using an anticoagulant-free container to examine MDA and NGF serum levels. MDA serum level was measured by using Beuge method with thiobarbituric acid, while NGF serum level was measured by using the ELISA method for human nerve growth factor-*β*.

The numerical data would be presented as mean and standard deviation. Data were analysed using Statistical Package for Social Sciences (SPSS) 22.0. The normality test was performed only for the numerical data using the Kolmogorov-Smirnov test. Correlation between MDA and NGF serum levels with peripheral diabetic neuropathy score were examined using the Spearman correlation test. The coefficient correlation was calculated and the level of significance for the correlation was counted. The level of statistical significance was 5%.

Results {#sec1-3}
=======

Patient's age in this study ranged from 41 to 59 years old. The range of the MDA serum level in this study was between 1.6 nmol/mL to 3.01 nmol/ml while the NGF serum level ranged from 6.8 pg/dl up to 15.7 pg/dl. The peripheral diabetic neuropathy score in this study is 3.53 (± 0.91)

###### 

Characteristics of the subjects

  Variable                    n (%)     mean (SD)
  --------------------------- --------- --------------
  Age (years)                           53.9 (5.7)
  Sex                                   
   Male                       13 (43)   
   Female                     17 (57)   
  Body Mass Index (Kg/m^2^)             24.6 (3.7)
  HbA1c (%)                             8.8 (2.0)
  Neuropathy score                      3.53 (0.91)
  MDA (nmol/mL)                         2.16 (0.28)
  NGF (pg/dL)                           10.56 (2.89)

There was a positive correlation (r = 0.364, p = 0.048) proved between the MDA serum level with diabetic peripheral neuropathy score ([Figure 1](#F1){ref-type="fig"}). The correlation between NGF serum level and diabetic peripheral neuropathy score was r = -0.59 and p = 0.001 ([Figure 2](#F2){ref-type="fig"}).
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Discussion {#sec1-4}
==========

The mean MDA serum level of this study was higher than normal. Maitreyess (2011) and Martin-Gallan (2003) has also found that MDA serum level on T2DM with complication was higher than the no complication group \[[@ref12]\], \[[@ref13]\]. Bhutia (2011) and Jalees (2017) found that the MDA serum level was significantly elevated in patients with diabetes compared to those in normal subjects \[[@ref14]\], \[[@ref15]\]. Zavar-Reza (2014) observed significant increased MDA serum level in T2DM patients with complications \[[@ref16]\]. Increased MDA serum level can be explained by increasing oxidative stress in diabetic patients. Increased level of oxidative stress associated with free radical-mediated lipid peroxidation. MDA serum level increased because of free oxygen radicals in diabetes that cause peroxidative breakdown of phospholipids.

In this study, the mean serum level of NGF was lower than normal. Mahmoud *et al*. in 2009 found a significant lower NGF serum level among patients with peripheral neuropathy \[[@ref17]\]. Obrosova *et al*., (2001) had shown that NGF serum level in the diabetic patient was lower than the control \[[@ref18]\]. Tosaki *et al*., (2008) reported that the Schwann cell planted on high-glucose culture media had a low concentration of NGF \[[@ref19]\]. Yilmaz *et al*., (2013) obtained the result of lower NGF production by the Schwann cell of diabetic subjects \[[@ref20]\]. NGF decline level is associated with the disturbances in Schwann cells regeneration because NGF produced by the neurons and the Schwann cells. The oxidative stress that occurs in diabetic patients will diminish the nutrient and oxygen supply for the nerve cells, resulting in interfering the life of the nerve and the Schwann cells and increasing the cell degeneration \[[@ref2]\], \[[@ref21]\].

In this study, we found a positive correlation between MDA serum level with diabetic peripheral neuropathy score. Aziza (2014) found that an increase of MDA serum level in diabetic neuropathy rats \[[@ref22]\]. Martinez-Hevaz (2017) reported that altered in MDA values is associated with polyneuropathy in diabetic patients \[[@ref23]\].

We found a significant negative correlation between NGF serum level with diabetic peripheral neuropathy score. Yasuda *et al*., (2003) discovered a positive correlation between decreasing NGF serum level and the neuron regeneration. NGF regulates intraneural homeostasis during development by providing neurotrophic and regulating intracellular pathways to promote neuronal sprouting \[[@ref11]\]. Li (2017) showed that NGF has a protective effect in diabetic peripheral neuropathy \[[@ref24]\].

In conclusion, there is a high MDA serum level and low NGF serum level in patients with diabetic peripheral neuropathy. Low NGF serum level play a bigger role than high MDA serum level in diabetic peripheral neuropathy.
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